Skeletal tissues (rat) were analyzed for ketamine (KET) and norketamine (NKET) following acute ketamine exposure (75 mg/kg i.p.) to examine the influence of bone type and decomposition period on drug levels. Following euthanasia, drug-free (n = 6) and drug-positive (n = 20) animals decomposed outdoors in rural Ontario for 0, 1, or 2 weeks. Skeletal remains were recovered and ground samples of various bones underwent passive methanolic extraction and analysis by GC-MS after solid-phase extraction. Drug levels, expressed as mass normalized response ratios, were compared across tissue types and decomposition periods. Bone type was a main effect (p < 0.05) for drug level and drug/metabolite level ratio (DMLR) for all decomposition times, except for DMLR after 2 weeks of decomposition. Mean drug level (KET and NKET) and DMLR varied by up to 23-fold, 18-fold, and 5-fold, respectively, between tissue types. Decomposition time was significantly related to DMLR, KET level, and NKET level in 3/7, 4/7, and 1/7 tissue types, respectively. Although substantial sitedependence may exist in measured bone drug levels, ratios of drug and metabolite levels should be investigated for utility in discrimination of drug administration patterns in forensic work.
Introduction
Investigations of the utility of skeletal tissues as an analytical matrix in postmortem toxicology (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) have been increasingly undertaken in recent years. Reports describing detection of various drugs in both fresh (1) (2) (3) (4) (5) (6) 15) and decomposed (7) (8) (9) (10) (11) (12) (13) (14) 16) skeletal tissues have been published, with some studies reporting substantial differences in measured drug levels between different bone types (16) . Other studies have shown that the effects of decomposition or some postmortem environments may lead to changes in the level of some drugs (8, 12, 13) , while others may not be affected. Overall, the existing data suggests that any value that bone drug measurements may have in terms of predicting toxicity is likely to be quite limited, certainly at the present time.
Recently, analysis was undertaken of skeletal remains of a single pig that had received a mixture of drugs including amitriptyline, citalopram, diazepam, and pentobarbital (16, 17) . The animal was then euthanized and permitted to decompose in a natural, outdoor environment for nearly two years. From that work, some important observations were made.
Firstly, the preparation of the porcine bones was was done differently than has been recently done in this laboratory for analysis of animal tissues that underwent a substantially shorter period of environmental exposure [e.g., previous experiments had permitted decomposition periods of little over 1 month for rats injected with various drugs (7, 10, 11, 14) ]. In preparing the porcine bones for analysis, there was no need for the wash steps that were used previously to remove soft tissues, which was done to minimize the influence of those tissues on drug measurements. Instead, a simple series of rinses (phosphate buffer, methanol, and acetone) were applied to each bone type, prior to pulverizing in preparation for analysis, without a more rigorous washing step based on ultrasonication (4) (5) (6) . In the analysis of the porcine bone, it was possible to sample a much larger mass of tissue (3 g vs. 0.5-1 g), and observed substantially higher drug levels than we have observed in analysis of rat bone using previously published methods (4) (5) (6) . Secondly, it was observed that there was a significant site dependence in the levels of all drugs analyzed, with the general trend that the largest levels were observed in bones near the central cavity (e.g., ribs, vertebrae) or those more peripheral bones with large marrow mass, relative trabecular bone content and blood perfusion (e.g., femoral epiphyseal bone). Finally, despite the substantial interbone variability in assay response, the ratio of levels of parent drug to those of the primary metabolite (e.g., amitriptyline and nortritpyline) were generally less variable, varying by 2-6-fold (17) . This observation has now provided more impetus to investigate whether the use of ratios of parent drug and metabolite levels can provide forensically relevant information in terms of the pattern of drug administration.
For example, it may be expected that an acute overdose may be characterized by a large excess of parent drug relative to metabolite in the blood, and this may be reflected in bone tissues. Conversely, a delayed death, or one following chronic exposure, may be characterized by a larger concentration of metabolite relative to parent drug. Importantly, various phenomena must be considered in such an investigation, such as the relative stability of parent drug and metabolites, analytical sensitivity, and the effects of postmortem environment (e.g., whether entomological activity influences the ratio of parent drug levels relative to metabolite levels).
This work was done to examine the extent of site-dependent variation of levels of ketamine (KET) and norketamine (NKET) in various bone types (vertebrae, pelvi, tibiae, femora, ribs, humeri, and ulna) of rats following acute KET administration, and to examine the influence of varying periods of decomposition on those measurements. Here, a less rigorous tissue clean up procedure was used, as was used in recent work with porcine tissues (16) , and this work was undertaken to determine if similar site-dependent variation in drug level would be observed with a different drug and multiple specimens from a different animal model (rat). This approach proved to substantially improve analytical sensitivity in the analysis of KET and NKET by GC-MS, relative to approaches used in this laboratory in the past (5).
Methods

Chemicals
Methanol used in drug extraction was HPLC grade and purchased from EMD Chemicals (Gibbstown, NJ). Drug standards (Cerilliant, Round Rock, TX) were obtained as 1 mg/mL methanolic solutions and diluted as required. All other chemicals were reagent grade and obtained from EMD Chemicals.
Animals and drug administration
Male Wistar rats (n = 20), which had been acutely exposed to KET, were graciously donated by Dr. T.C. Tai of the Northern Ontario Medical School. Rats were given 75 mg/kg KET (i.p.) and euthanized with CO 2 within 20 min of drug administration. This dose was chosen as it is a non-fatal anesthetic dose in rats. One group of KET-positive rats (n = 4) were dissected for various skeletal tissues prior to decomposition (the fresh tissue group). All other remains were placed in secure cages, and were left to decompose outdoors at a rural Ontario site during early summer (June), with full exposure to sunlight and other weather features (precipitation, etc.) for 1 or 2 weeks. Drug-free rats (n = 6) were used as controls, with 2 control animals used for each decomposition interval (i.e., 0, 1, or 2 weeks). Bones, including vertebrae, pelvi, tibiae, femora, scapulae, radii, ulnae, and humeri, were collected from all animals for analysis.
Bone preparation and passive drug extraction
Bones were separated according to type (e.g., vertebra vs. pelvis) and source animal (e.g., Decomp. 2 weeks -Animal 1). All bones were washed sequentially with phosphate buffer (PB6: 0.1 M, pH 6.0), methanol, and acetone to remove loosely bound soil and other contaminants. Bones were then dried in test tubes at 50°C. The different bone types were ground into fine particles using a domestic grinder. Bone samples (approximately 0.4-0.6 g) of each type were placed in glass screw-cap tubes (20 mL). The bone masses sampled corresponded to the entirety of the tibial or humeral bone, and this sampled mass was maintained across all tissue types to minimize the likelihood that the tissue mass sampled would influence the measurements of relative drug distribution. Methanol (3 mL) was added to each tube. Samples were incubated on a hot plate at 50°C (± 1-2°C) for a period of 72 h. Following each solvent recovery, bones were washed twice with 3 mL methanol and the methanol washes were pooled with the originally recovered fraction. All recovered methanol fractions were then evaporated under a gentle stream of air at 70°C. The samples were reconstituted in 1 mL of phosphate buffer (PB6).
Solid-phase extraction (SPE)
Internal standard [200 ng ketamine-d 4 (KET-d 4 )] was added to each sample, and each sample solution was then combined with 100 µL glacial acetic acid, and 3 mL cold acetonitrile/ methanol (1:1, v/v) and stored at -20°C for approximately 1 h to precipitate lipids and proteins. The samples were centrifuged (3700 rpm) for 10 min, and the supernatant was evaporated to approximately 1 mL under a gentle stream of air at 70°C. Each supernatant was then centrifuged and concentrated to approximately 1 mL as described. Each sample was then diluted to 5 mL with PB6 and then underwent SPE.
SPE was performed using CleanScreen XCEL 1 columns (3 cc, 130 mg, United Chemical Technologies, Bristol, PA). Columns were conditioned with 3 mL of methanol and deionized water followed by 3 mL PB6. Samples were loaded and allowed to flow by gravity. The columns were then washed sequentially with PB6 (3 mL) and 0.1 M acetic acid (3 mL), dried under vacuum (10 in. Hg, approximately 5 min), washed again with methanol (3 mL), and dried again under vacuum (10 in. Hg, 10 min). Analytes were eluted using two 3-mL portions of 80:17:3 ethyl acetate/isopropanol/ammonium hydroxide. Extracts were then evaporated to dryness under a gentle stream of air (70°C) and reconstituted in 100 µL ethyl acetate for analysis by gas chromatography-mass spectrometry (GC-MS).
GC-MS
Extracts were analyzed on a PerkinElmer Clarus 600C GC-MS (PerkinElmer LAS, Shelton, CT) using electron impact ionization, in the selected ion monitoring (SIM) mode.
Separation was achieved using a ZB-Drug-1 column (15 m × 0.25 mm × 0.25 µm, Phenomenex, Torrance, CA). Extracts (2 µL) were injected into the injector, which was maintained at 250°C. The GC oven temperature was initially set to 60°C and held constant for 3 min.
The set temperature was directly increased to 190°C at a rate of 130°C/min and then increased to 240°C at a rate of 4°C/min. The oven temperature was then set to directly increase to 300°C and held at that temperature for 3 min at the end of the analytical run. The total GC-MS run time was roughly 20 min.
The ions monitored were m/z 180, 167, and 152 for KET (underlined ion used for quantitative analysis), m/z 166, 165, and 131 for NKET, and m/z 184, 213, and 156 for KET-d 4 . The response ratio (RR) is defined as the ratio of peak area for the quantitation ion (m/z 180 or 166) to that of the ion with m/z 184 corresponding to KET-d 4 . Example mass chromatograms for the quantitation ions of KET, NKET, and KET-d 4 are shown in Figure 1 , corresponding to an analysis of a vertebral bone sample of an animal from the 1-week decomposition period.
Performance characteristics of the GC-MS analysis of KET and NKET-precision and linearity of response
The precision [% coefficient of variation, %CV, of measured ratios of response of the m/z 180 (KET), 166 (NKET), and 184 (KET-d 4 ) ions, respectively] of replicate analyses (n = 3) of matrix-matched spiked bone extracts ranged from 3 to 20%. The drug-free matrix for method validation was created by sonication of roughly 100 g drug-free bone, following outdoor decomposition, in PB6 (approximately 400 mL). All calibrants were prepared in 1-mL aliquots of this matrix, prior to the lipid/protein precipitation and SPE steps, in the same manner that control bone and KET-exposed bone samples were treated. The limit of detection for both KET and NKET was approximately 10 ng/mL, based on the lowest concentration assayed that could be differentiated from the drug-free controls.
The assay was shown to be linear for both analytes from 10-2000 ng/mL [R 2 (KET) = 0.9996, R 2 (NKET) = 0.9942]. The concentration dependence of the GC-MS assay is illustrated in Figure 2 .
Statistical analysis
Statistical analysis of data was done using the KruskallWallis test, a non-parametric analysis of variance, using StatPlus 2009 software (AnalystSoft). The Kruskall-Wallis test was utilized to compare the variability within replicate extractions of a given bone type to the variability in analytical response across all tissues assayed, in order to determine whether any significant tissue-dependent distribution existed. This nonparametric test was chosen because it does not presume that measured values within a group are normally distributed.
Results
For purposes of comparison, drug levels were expressed as the mass-normalized response ratios (RR/m) for KET and NKET measurements in each of the tissues examined. Importantly, it is not possible to accurately measure the recovery of drug extracted from a solid bone sample with conventional toxicological techniques (e.g., GC-MS). It is also not possible to properly calibrate the assay response with respect to drug concentration in a solid bone sample, since a drug standard cannot be homogeneously aliquoted into a solid matrix and mixed as can be done with fluids such as blood or urine. Because this work was concerned with the effect of tissue type sampled and decomposition interval on the relative level of drug in one bone versus another, bone drug concentrations were not computed.
Instead, our approach to data analysis uses a relative comparison of assay response (i.e., the response ratio, RR), normalized to account for tissue mass sampled (i.e., RR/m), which is directly related to bone drug concentration (Figure 2 ). For ease of reading, we refer to the RR/m measurement as "drug level", because it is indicative of, but not identical to, drug concentration in a given bone sample. Nonetheless, we provide estimates of drug concentrations, but these values must be considered as approximate for the reasons outlined. Ketamine was detected in all samples assayed with the exception of one ulnar bone sample. Estimates of KET concentrations in bone tissue ranged from 60 to 10,900 ng/g. Norketamine was detected in the majority of samples assayed, with the exception of three samples of ulnar bone and two samples of humeral bone. Estimates of NKET concentrations in bone tissue ranged from undetectable to 5260 ng/g. The measured drug levels (i.e., RR/m) are summarized in Table I , along with the ratio of levels for KET and NKET (ie., RR KET /RR NKET ) for each tissue analyzed. For KET, the RR values were above the limit of detection and within the linear range of the assay for all samples assayed except for one ulnar sample from the 1-week decomposition period (excluded from analysis). These data are summarized graphically in Figure 3 . Nonparametric analysis of variance (Kruskall-Wallis test) was done to determine whether bone type or decomposition period was a main effect for the observed drug levels for KET or NKET, or for the ratio of drug levels values for KET and NKET (RR KET /RR NKET ). For KET analyses, mean levels ranged from 3 to 51, 2 to 30, and 6 to 51 g -1 for the 0-, 1-, and 2-week decomposition periods, respectively. Kruskall-Wallis analysis showed bone type to be a main effect for drug level, with the greatest values generally observed in the vertebrae, and the lowest values were generally observed in the humeral and ulnar samples.
For NKET analyses, the RR values were above the limit of detection and within the linear range of the assay for all samples assayed except for two humeral bone samples and three ulnar samples (excluded from analysis). Mean levels (RR/m) ranged from 0.9 to 13, 0.8 to 5, and 1 to 4 g -1 for the 0-, 1-, and 2-week decomposition periods, respectively. Kruskall-Wallis analysis showed bone type to be a main effect for the NKET levels, and the greatest values were again generally observed in the vertebrae, and the lowest values were generally observed in the humeral and ulnar samples. Examination of the ratio of levels for KET to that of NKET (i.e., RR KET /RR NKET ) for each bone sample assayed showed mean ratios ranged from 4 to 11, 2 to 7, and 6 to 13 for the 0-, 1-, and 2-week decomposition periods, respectively. Kruskall-Wallis analysis showed bone type to be a main effect for the ratio of drug and metabolite levels for samples from all decomposition intervals examined.
Examining data across all tissue samples assayed, including all decomposition intervals, drug levels (excluding those samples where either KET or NKET was not detected) varied 325-fold and 64-fold, for KET and NKET, respectively, while the ratio of assay responses, (RR KET /RR NKET ) varied by 24-fold across all tissue samples analyzed. The relative variabilities, expressed as the ratio of maximum to minimum RR/m values within a given animal and across animals for a given tissue type and decomposition interval, are summarized in Table II .
Data analysis showed decomposition interval to be significantly related to the ratio of drug and metabolite levels, KET level, and NKET level in 3/7, 4/7, and 1/7 tissue types, respectively.
Discussion
The purpose of this work was to assess the relative distribution of KET and NKET across various skeletal tissues and to examine the effect of the period of decomposition on this distribution. In so doing, a number of issues can be addressed. First, it is important to determine if there is a particular bone type that is preferential for analysis for drugs and metabolites. Secondly, if there is significant variation in bone drug levels within a given body, then it must be determined whether it is suitable to compare the measured level in one bone type to levels in a reference database corresponding to another bone type (e.g., comparing vertebral bone drug levels to femoral bone drug levels). This is similar in kind to the question of whether it is appropriate to compare drug levels in peripheral blood to a database corresponding to levels measured in central blood. Finally, the effects of decomposition on such measurements Ketamine (KET) 0 51 ± 11 47 ± 36 33 ± 9 16 ± 7 15 ± 9 4 ± 2 3 ± 2 1 30 ± 22 16 ± 13 13 ± 10 18 ± 7 6 ± 4 9 ± 4 2 ± 1 2 51 ± 30 20 ± 5 12 ± 10 17 ± 9 12 ± 4 7 ± 5 6 ± 3
Norketamine (NKET) 0 14 ± 8 3 ± 1 3.1 ± 0.9 1.9 ± 0.9 4 ± 2 1.3 ± 0.5 0.9 ± 0.5 1 5 ± 3 5 ± 3 2 ± 1 2.5 ± 0.9 3.4 ± 2.7 2 ± 2 0.8 ± 0.5 2 4 ± 2 3 ± 2 2 ± 1 1.8 ± 0.9 1.9 ± 0.7 1 ± 1 1.1 ± 0.5 KET/NKET 0 5 ± 2 11 ± 7 11 ± 8 10 ± 5 4 ± 1 5 ± 2 3.9 ± 0.9 1 6 ± 2 7 ± 7 7 ± 4 7 ± 2 2.2 ± 0.6 4 ± 2 3.0 ± 0.7 2 13 ± 5 8 ± 4 7 ± 3 70 ± 5 6 ± 2 6 ± 2 5 ± 3
should be clarified because bones will not generally be used as a matrix for analysis except in the most advanced cases of decomposition, where there are few other matrices from which to choose.
Data treatment
As discussed previously (14, 16) , data were compared using the RR/m parameter because drug recovery from skeletal tissues cannot be quantified accurately. As the response ratio (RR) was shown to vary linearly with drug concentration (Figure 2 ) and because those values were normalized to account for differences in analytical response due to differences in tissue mass sampled, comparison of drug levels (expressed as RR/m values) is equivalent to comparison of drug concentrations in tissue extracts. This approach allows for examination of the effects of experimental variables of the type of bone sampled and the extent of decomposition by comparison of relative drug levels between samples.
Implications of data
With respect to bone type, substantial interbone variability in measured drug levels was noted, both within a bone type from a given group of animals and between different bones from any one given animal. Tissue type was a main effect for level for both KET and NKET, and for the ratio of drug and metabolite levels (RR KET /RR NKET ) in all cases. Decomposition interval significantly influenced levels for both KET and NKET in 4/7 and 1/7 bone types, respectively, but was a main effect for ratio of drug and metabolite levels in 3/7 bone types. Overall, the data in Figure 3 and Table I suggest that there may be limited quantitative interpretive value in any individual drug or metabolite measurement in skeletal tissue, in the absence of a large and comprehensive database of drug levels in various bone types, collected from numerous cases using standardized sample preparation methodologies. Still, it is important to consider that valuable forensic information may be gleaned from these data. This may be seen following consideration of the magnitude of variability in the various parameters measured (i.e., drug level in different bone types, or ratio of drug and metabolite levels vs. decomposition interval). The data in Table II summarize the relative range of values observed in the drug levels and the ratios of drug and metabolite levels by expressing them as the ratio of maximum to minimum values (MAX/MIN) observed for each measurement, within each animal, and across animals within a given tissue type. Some general trends are apparent within this data. First, the relative variability tended to be larger in tissues with lower drug level measurements (e.g., humerus, ulna). This may be related to the degree of exposure of that bone to the drug via normal distribution and redistribution effects and implies that certain bone types are likely to provide more reliable interpretive value than others. Hence, the type of bone sampled in casework should be that where drug levels may be expected to be highest. From our work thus far (10, 11, 14, 16, 17) , the sites where the largest drug levels are likely to be found are vertebral bone, pelvic bone, or trabecular femoral bone. Secondly, the relative variability between samples within a particular tissue group (e.g., within the vertebral or femoral bone group) tended to be near the lower end of the range of relative variability within different bone types from any one given animal. This suggests that a given bone drug level should be interpreted relative to a database of drug levels measured in the same bone type. For example, a given drug level measured in vertebral bone should ideally only be compared to other drug levels measured in vertebral bone for purposes of interpretation. Furthermore, variability in measurements may be minimized by choosing a tissue which displays the greatest tendency toward high drug levels (e.g., vertebrae, pelvi). In general, under these fixed dose-conditions, site-dependent variation within a given animal was greater than variation in measurements of a particular tissue between animals. Finally, ratios of drug and metabolite levels (i.e., RR KET /RR NKET ) were generally less variable than the drug levels themselves in the corresponding tissues, or within a given animal. This trend was observed in earlier work with porcine bone (16, 17) , and implies that the use of quantitative relationships between parent drug and metabolite levels may provide more precise indications of the circumstances of drug exposure (e.g., fatal acute overdose vs. non-fatal chronic exposure).
An important consideration for any interpretation of drug and metabolite measurements in bone is the influence of decomposition processes on measured levels. Possible influences of decomposition include postmortem metabolism through insect or microbial activity or through chemical hydrolysis, or drug or metabolite loss through mass transport phenomena as the soft tissues and fatty deposits are liquefied. Importantly, these influences may be expected to be drug-dependent, and factors including the volume of distribution of parent drug and metabolite and drug stability may be relevant. In this work, decomposition interval significantly influenced KET level in 4/7 tissue types, but only influenced NKET in 1/7 tissue types investigated. Ratios of KET and NKET levels were significantly influenced by decomposition interval in 3/7 tissue types examined. In all three cases of a significant influence of decomposition interval on the ratio of KET and NKET levels, either the KET or NKET level was also significantly influenced. However, there was little evidence of any regular correlation between drug level (KET or NKET) and decomposition interval, or between ratio of KET and NKET levels and decomposition interval. It is not possible at this time to ascertain the mechanism by which decomposition processes are exerting an influence. Further work is required to determine if drug breakdown occurs to a significant extent or if decomposition is influential by some other mechanism and the extent to which this effect is significant over larger numbers of samples.
Conclusions
The findings in this work suggest that considerable site-dependent variability in measured drug and metabolite levels may be observed in toxicological analysis of skeletal tissues, but that the ratio of parent drug levels to those of the primary metabolite in a given tissue may be less prone to variation based on sampling and environmental parameters. These data are consistent with earlier experimental findings done using a different animal model (pig) and set of drugs (16) .
The period of decomposition may influence drug and metabolite measurements, although the extent to which it will affect the ability to discriminate between different circumstances of drug exposure is unknown and requires further investigation. Future work in this laboratory will investigate the utility of relationships between parent drug and metabolite levels in differentiation of drug exposure patterns under various conditions of postmortem environment. * Ratio of maximum and minimum drug levels and drug level ratios in different bone types within each animal are also shown for the different decomposition periods investigated.
